The men were randomised to Weight Watchers weight loss programme plus placebo versus the same weight loss programme plus testosterone(T) alone, based on criteria from our previous study.18 Outcome measures The primary outcome was change from baseline to 6 months after cessation of treatment, gym steroids for sale. Secondary outcomes of interest were weight change for the treated arms and measures of change in cardiovascular risk factors, including waist circumference, blood pressure, plasma HDL cholesterol, and waist-to-hip ratio, buy muscle building steroids online. Body mass index was the primary outcome measure and outcomes adjusted for sex, age and body density (kg/m2).19-21 A subgroup analysis was conducted with the treatment arms adjusted for age, sex and obesity status. Statistical analysis A random-effects model was used to account for the heterogeneity of the outcome.22 We report mean, 95% confidence intervals (CIs) and P values to assess the differences between groups. Because the weight loss and cardiovascular risk factors data for the treated groups were collected only at 6 months, we estimated risk of change over time from baseline to 6 months using the repeated-measures Cox proportional hazards model assuming the same weights for time units and covariates.23 The repeated-measures Cox model was used to assess the effect modification by time. All statistical tests were two-tailed in an attempt to account for the potential confounding by time. To account for nonresponse (at baseline, or at 6 months) we analysed data by using a random-effects model where baseline was the same for all participants, but where the same baseline characteristics were adjusted for in each case.24 Study population The study population consisted of women aged 40 to 65 years, without cardiovascular disease, diabetes mellitus or cancer, utah drug possession laws 2022. We excluded women with abnormal body mass index, obesity (BMI >40 kg/m2) or type 2 diabetes and women with an indication to lose weight or who were overweight or obese, steroid fermentation. Weight was ascertained by body-composition assessment using an enzymatic methods (Kellogg's KDC-1100 scales), the International Classification of Diseases for Oncology (ICD-O-3), ICD9 and ICD10.25 The study was approved by the London Health Sciences Ethics Committee and registered at ClinicalTrials.gov before randomisation, and all participants gave written informed consent. Assessment of cardiovascular risk factors Body weight was assessed to the nearest 0.2 kg with the use of a standard KDC-1100 scale,26 which is widely used in the UK for body-composition assessment.